Skip to main content
GutCited

Lactobacillus reuteri için Bloating and Intestinal Gas

B Kanıt Bunu büyük ölçüde tutarlı sonuçlarla en az bir randomize çalışma desteklemektedir.

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dreuteri\u0026condition\u003Dbloating\u002Dand\u002Dgas'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            B

        

        

            
Sonuç

            
            
Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    basic science
                
                
                
                
            

            
                Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
            
            

                
                Dose: Lactobacillus reuteri E9 (dose not specified)
                
                
                vs: Placebo
                
                
                
                Etki: None
                
                
                < 0.05
                
            

            
        

        
        

            

                
                    Observational Study
                
                
                n=65
                
                
                
                Open-label
                
            

            
                Incidence and Characterization of SIBO in NAFLD Patients.
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: SIBO prevalence in NAFLD patients
                
                
                Etki: SIBO in 37%; post-treatment 4% remained+
                
                
                None
                
            

            
            
Popülasyon: Adults with NAFLD diagnosed via FibroScan

            
        

        
        

            

                
                    Randomized Controlled Trial
                
                
                n=56
                
                
                15 weeks
                
                
                Double-blind
                
            

            
                Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and …
            
            

                
                Dose: 4x10^8 CFU (induction), 2x10^8 CFU (standard)
                
                
                vs: Placebo
                
                
                Outcome: Constipation symptoms and QoL (Constipaq/CSS)
                
                
                Etki: None
                
                
                pP0.05
                
            

            
            
Popülasyon: Adults with functional constipation

            
        

        
        

            

                
                    Other
                
                
                n=54
                
                
                
                Double-blind
                
            

            
                Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, …
            
            

                
                Dose: None
                
                
                vs: Simethicone
                
                
                Outcome: Safety and efficacy for functional bloating
                
                
                Etki: None
                
                
                pP0.008
                
            

            
            
Popülasyon: Adults with functional bloating

            
        

        
        

            

                
                    Meta-Analysis
                
                
                n=3122
                
                
                
            

            
                Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a …
            
            

                
                Dose: None
                
                
                vs: Triple therapy alone/placebo
                
                
                Outcome: H. pylori eradication rate and side effects
                
                
                Etki: None
                
                
                None
                
            

            
            
Popülasyon: Children with H. pylori infection

            
        

        
        

            

                
                    Randomized Controlled Trial
                
                
                n=101
                
                
                16 weeks
                
                
                Double-blind
                
            

            
                Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, …
            
            

                
                Dose: L. reuteri DSM 17938 (1e8 CFU twice daily)
                
                
                vs: placebo
                
                
                Outcome: abdominal pain severity (Wong-Baker FACES)
                
                
                Etki: None
                
                
                None
                
            

            
            
Popülasyon: Children aged 6-15 with functional abdominal pain

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
7

        
Çalışmalar

    

    

        
500

        
Katılımcılar

    

    

        
            
            ↑
            
        
        
Positive

    

    

        B

        
Derece

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Frontiers in bioscience …
                        2025
                        
                    

                

                
                

                    

                        
                            Incidence and Characterization of SIBO in NAFLD Patients.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Euroasian journal of …
                        2025
                        
                    

                

                
                

                    

                        
                            Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation.
                        
                        
                            
                                RCT
                            
                            
                            
                        
                    

                    

                        Beneficial microbes
                        2018
                        
                        35 atıf
                        
                    

                

                
                

                    

                        
                            Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical …
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Translational gastroenterology and …
                        2018
                        
                        24 atıf
                        
                    

                

                
                

                    

                        
                            Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis.
                        
                        
                            
                                Meta-Analysis
                            
                            
                            
                        
                    

                    

                        European journal of …
                        2017
                        
                        93 atıf
                        
                    

                

                
                

                    

                        
                            Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial.
                        
                        
                            
                                RCT
                            
                            
                            
                        
                    

                    

                        The Journal of …
                        2016
                        
                        84 atıf
                        
                    

                

                
                

                    

                        
                            Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Middle East journal …
                        2013
                        
                        13 atıf
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
Yaygın Kullanılan Dozajlar

                

                    
                    

                        
general:

                        
100 million - 5 billion CFU/day

                    

                    
                    

                        
infantilecolic:

                        
100 million CFU/day (DSM 17938 strain, 5 drops)

                    

                    
                    

                        
adultgisupport:

                        
1-5 billion CFU/day

                    

                    
                

                
                

                    Üst sınır: Well-tolerated up to 10 billion CFU/day in clinical trials
                

                
            

            

            
            

                
Araştırmalarda İncelenen Dozajlar

                

                    

                        
                            

                                Dozaj
                                Süre
                                Etki
                                N
                            

                        
                        
                            
                            

                                Lactobacillus reuteri E9 (dose not specified)
                                --
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                65
                            

                            
                            

                                4x10^8 CFU (induction), 2x10^8 CFU (standard)
                                15 weeks
                                
                                    
                                    Positive
                                    
                                
                                56
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                54
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                3122
                            

                            
                            

                                L. reuteri DSM 17938 (1e8 CFU twice daily)
                                16 weeks
                                
                                    
                                    Positive
                                    
                                
                                101
                            

                            
                            

                                None
                                4 weeks
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                En iyi alım zamanı: Before meals or on empty stomach; for infants, add drops to breast milk or formula
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
Bildirilen Yan Etkiler

                    
    
                        
                        
  • 
                            ⚠
                            Mild gas in initial days of use
                        
    • 
                        
                        
  • 
                            ⚠
                            Occasional increased fussiness in infants during adjustment (transient)
                        
    • 
                        
                        
  • 
                            ⚠
                            Rare loose stools
                        
    • 
                        
                        
  • 
                            ⚠
                            Very rare: bacteremia in immunocompromised individuals
                        
    • 
                        
                    

                

                

                
                

                    
Bilinen Etkileşimler

                    
    
                        
                        
  • 
                            ●
                            Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
                        
    • 
                        
                        
  • 
                            ●
                            Immunosuppressants (theoretical risk in immunocompromised patients)
                        
    • 
                        
                        
  • 
                            ●
                            Proton pump inhibitors (altered gastric pH may affect colonization)
                        
    • 
                        
                    

                

                

                
                

                    

                        Tolere edilebilir üst alım: Well-tolerated up to 10 billion CFU/day in clinical trials
                    

                

                
            

            

                Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Lactobacillus reuteri help with Bloating and Intestinal Gas?
            
        
        

            Based on 7 studies with 500 participants, there is moderate evidence from clinical studies that Lactobacillus reuteri may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
        

    

    
    

        
            How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?
            
        
        

            Studies have used various dosages. A commonly studied range is 100 million - 5 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Lactobacillus reuteri?
            
        
        

            Reported side effects may include Mild gas in initial days of use, Occasional increased fussiness in infants during adjustment (transient), Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?
            
        
        

            We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  




            

                
                
                

                
                

                    
Lactobacillus reuteri diğer sağlık durumları için

                    

                        
                        
                            Gastroesophageal Reflux Disease (GERD)
                            C

                        
                        
                    

                

                
            

        

        

    


    
    






  
References

  
    
    
    
  1. 
      [1]
      Yongcheng Jiang et al..
      Front Biosci (Landmark Ed).
      2025.
      Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
      doi:10.31083/FBL39587
      PubMed
    
    2. 
    
    
  2. 
      [2]
      Shamim Naizr et al..
      Euroasian J Hepatogastroenterol.
      2025.
      Incidence and Characterization of SIBO in NAFLD Patients.
      doi:10.5005/jp-journals-10018-1468
      PubMed
    
    3. 
    
    
  3. 
      [3]
      G Riezzo et al..
      Benef Microbes.
      2018.
      Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation.
      doi:10.3920/BM2017.0049
      PubMed
    
    4. 
    
    
  4. 
      [4]
      Ovidiu Burta et al..
      Transl Gastroenterol Hepatol.
      2018.
      Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical …
      doi:10.21037/tgh.2018.09.11
      PubMed
    
    5. 
    
    
  5. 
      [5]
      Jue-Rong Feng et al..
      Eur J Clin Pharmacol.
      2017.
      Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis.
      doi:10.1007/s00228-017-2291-6
      PubMed
    
    6. 
    
    
  6. 
      [6]
      Zvi Weizman et al..
      J Pediatr.
      2016.
      Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial.
      doi:10.1016/j.jpeds.2016.04.003
      PubMed
    
    7. 
    
    
  7. 
      [7]
      Behnaz Amirimani et al..
      Middle East J Dig Dis.
      2013.
      Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial.
      
      PubMed
    
    8. 
    
  















    

        FDA Sorumluluk Reddi:
        Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.